Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5664039 | Critical Reviews in Oncology/Hematology | 2017 | 6 Pages |
Abstract
Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Bruno Vincenzi, Giuseppe Badalamenti, Andrea Napolitano, Mariella Spalato Ceruso, Francesco Pantano, Giovanni Grignani, Antonio Russo, Daniele Santini, Massimo Aglietta, Giuseppe Tonini,